Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

VeraChem is pleased to announce the release of VM2 3.0, the latest version of its software for the calculation of protein-ligand and host-guest binding free energies.

VM2 3.0 includes an end-to-end workflow capability that automates system setup and forcefield typing/parameter assignment, ligand 2D to 3D conversion, generation of initial receptor-ligand conformations, submission of free energy calculations via resource managers, and collection and organization of final binding free energy results. Extensive benchmarking of VM2 3.0 predicted binding free...

VeraChem’s development team present the VM2 protein-ligand binding free energy method at Janssen Pharmaceutical

VeraChem’s development team carry out a presentation of the VM2 protein-ligand binding free energy method at Janssen Pharmaceutical, and make agreement for trial usage of the VM2 software package.

VeraChem’s development team carry out presentation of the VM2 protein-ligand binding free energy method at Dart NeuroScience

VeraChem’s development team carry out a presentation of the VM2 protein-ligand binding free energy method at Dart NeuroScience LLC, and make agreement for trial usage of the VM2 software package.

VeraChem software now licensed to over 500 academic researchers worldwide

VeraChem software now licensed to over 500 academic researchers worldwide

VeraChem’s software now licensed to over 500 academic researchers worldwide.

VeraChem licenses its software

VeraChem licenses its software

VeraChem licenses its novel protein-ligand binding affinity software to a major pharmaceutical company.